(If a Generation® Plus test is requested, your sample will
be sent to an accredited laboratory in California.)
Generation® test. If your doctor recommends the Generation®
Plus test, the results will be available in 9-14 days from collection due to shipping
cord blood stem cell banking for your baby at birth
As this website contains only general education information, professional advice from your medical
practitioner should be sought before applying the information in this website to particular circumstances. You
should not rely on any information contained in this website without first obtaining professional advice. Prices
are correct at time of publishing and are subject to change without notice.
What is the Generation® non-invasive prenatal test?
Non-invasive prenatal testing (NIPT) is a revolutionary advance in prenatal screening which can detect genetic
material (DNA) from the placenta in a blood test from the mother. In the past, the ability to test DNA from the
fetus required much more invasive methods such as amniocentesis or placental biopsies, which are not without
risks to mothers and their babies. NIPT is a simple and highly accurate test which may help avoid more invasive
techniques of prenatal testing.
The Generation® non-invasive prenatal test (NIPT) screens for the most common chromosomal abnormalities
that can affect your baby’s future health using a simple blood test. The Generation® NIPT is available from
as early as the 10th week of pregnancy, for both singleton and twin pregnancies.
How does the Generation® test work?
During pregnancy, some of the baby’s DNA from the placenta crosses into your bloodstream. A sample of your
blood is drawn from you, and the Generation® NIPT tests this DNA to identify
certain chromosome conditions in your pregnancy. The Generation® test takes a
deeper approach to the science, using an advanced technology called “Massively Parallel Sequencing” to analyse
millions of DNA fragments per sample and accurately count the number of chromosomes present and determine if
there are too many or too few copies of the tested chromosomes in your baby.
Why the Generation® test?
The Generation® test can be used to obtain important information about the
health of your developing baby, simply, accurately and in the first trimester (at 10 weeks), with little or no
risk to the pregnancy.
This screening test may be an option for you to consider if:
In addition, clinical best practice guidelines from Australian and international medical societies recommend
that all pregnant women, regardless of risk status, be offered the opportunity for discussion and choice
regarding NIPT and other available prenatal screening and diagnostic tests.
What kind of conditions can the Generation® test detect?
Chromosomes normally come in pairs. Most people have 23 pairs of chromosomes, with one pair which determines
sex. Men normally have an XY pair of sex chromosomes, and women normally have an XX pair of sex chromosomes. Any
more or less can lead to mental or physical disabilities, with different levels of severity.
The Generation® NIPT looks for two few (missing) or too many (extra) copies of
chromosomes, which are often associated with these disabilities. The most commonly seen and tested for
all of which can be accurately detected with the Generation® test.
If the Generation® Plus test is requested by your doctor, more rarely
occurring microdeletion genetic syndromes are also tested for. These microdeletion syndromes are caused by the
loss of a small piece of a chromosome and testing might be recommended by your doctor for a number of clinical
reasons. The Generation® Plus test cannot be performed on twins.
How will my test be reported?
Your test report will include one of two possible results for chromosomes 21, 18 and 13:
Do normal Generation® test results mean that my baby will be
that my baby will be perfectly healthy?
The Generation® prenatal test is a highly accurate advanced screening test that
is non-invasive. No test, however, can guarantee a baby will not have any medical issues.
The Generation® test only addresses aneuploidies of chromosomes 21, 18, 13, and
sex chromosomes†. It does not test for, or report all, genetic and non-genetic problems that may be
present in a baby.
†Sex chromosome aneuploidy testing is available for singleton pregnancies
Why did we choose the Generation® test?
The Generation® test was chosen for development by Genomic Diagnostics based on
a careful evaluation of its quality and proven scientific performance.
The performance of the Generation® prenatal test has been evaluated and
published in numerous major studies, including clinical experience in over 34,000 patients from over 60 leading
US medical research and teaching institutions1. Those findings
have subsequently been replicated in other studies2,3,4, including the New
England Journal of Medicine, one of the most prestigious international medical journals. These studies have found
that the test performed substantially better than conventional tests under regular clinical conditions, with 1 in
4,000 false negative results, 1 in 500 false positive results, and the lowest test failure rate of any non-
invasive prenatal test.
How do I organise to have the Generation® test?
conveniently located Generation® collection centre
to the lab for testing
Does Medicare or private health insurance cover the cost of the
Generation® prenatal test?
The Generation® prenatal test does not qualify for a Medicare rebate. The total
out-of-pocket cost to the patient for the standard test for chromosomes 13, 18, 21 and sex chromosomes is
$395* (Please enquire for pricing of Generation® Plus), which
is payable prior to sample collection by calling our Customer Care Team on 1800 822 999.
*Prices are subject to change.
1. Bhatt S, Parsa S, Snyder H, et al. Clinical
Laboratory Experience with Noninvasive Prenatal Testing: Update on Clincially Relevant Metrics. ISPD 2014
2. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal
plasma DNA sequencing. Obstet Gynecol. 2012;119:890-901.
3. Futch T, Spinosa J, Bhatt S, de Feo E, Rava RP,
Sehnert AJ. Initial clinical laboratory experience in non-invasive prenatal testing for fetal aneuploidy from
maternal plasma DNA samples. Prenat Diagn. 2013;33:569-574.
4. Bianchi DW, Parker RL, Wentworth J et al. DNA
Sequencing versus Standard Prenatal Aneuploidy Screening. N Engl J Med 2014; 370:799-808.
Health, Inc. (2012) Analytical Validation of the verifi Prenatal Test: Enhanced Test Performance For Detecting
Trisomies 21, 18 and 13 and the Option for Classification of Sex Chromosome Status. Redwood City, CA.
In addition, clinical best practice guidelines
from Australian and international medical societies recommend that all pregnant women, regardless of risk status,
be offered the opportunity for discussion and choice regarding NIPT and other available prenatal screening and